Graphene Investments SAS Sells 3,000 Shares of IQVIA Holdings Inc. $IQV

Graphene Investments SAS lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 16.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,400 shares of the medical research company’s stock after selling 3,000 shares during the quarter. Graphene Investments SAS’s holdings in IQVIA were worth $2,925,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC increased its stake in IQVIA by 57.3% in the third quarter. GAMMA Investing LLC now owns 3,414 shares of the medical research company’s stock valued at $648,000 after purchasing an additional 1,244 shares in the last quarter. Praxis Investment Management Inc. bought a new stake in IQVIA in the 3rd quarter valued at about $426,000. Osaic Holdings Inc. raised its stake in IQVIA by 32.0% during the 2nd quarter. Osaic Holdings Inc. now owns 71,103 shares of the medical research company’s stock worth $11,233,000 after buying an additional 17,217 shares during the period. Orion Porfolio Solutions LLC boosted its holdings in IQVIA by 7.0% in the second quarter. Orion Porfolio Solutions LLC now owns 19,552 shares of the medical research company’s stock worth $3,081,000 after acquiring an additional 1,282 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in IQVIA in the second quarter valued at approximately $242,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.9%

Shares of IQV stock opened at $221.56 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The company has a market capitalization of $37.73 billion, a price-to-earnings ratio of 30.39, a PEG ratio of 2.51 and a beta of 1.37. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The company has a 50-day simple moving average of $217.81 and a two-hundred day simple moving average of $191.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. TD Cowen cut IQVIA from a “buy” rating to a “hold” rating and increased their target price for the stock from $206.00 to $215.00 in a report on Monday, November 3rd. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Barclays set a $230.00 price objective on shares of IQVIA in a report on Monday. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Finally, Citigroup boosted their price objective on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $243.59.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.